ArticleJournal of pain research2018
Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis.
Article in Journal of pain research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review.Clinical and experimental dental research · 2024Pooled it
- Efficacy and safety of subcutaneous injection of botulinum toxin in the treatment of Chinese postherpetic neuralgia compared to analgesics: a systematic review of randomized controlled trials and meta-analysis.Frontiers in neurology · 2024Pooled it
- A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain.Toxins · 2022Pooled it
- Microcurrent technology for rapid relief of sinus pain: a randomized, placebo-controlled, double-blinded clinical trial.International forum of allergy & rhinology · 2019Trial
- Review
- Impact of botulinum toxin type A on ocular pain with neuropathic features.The ocular surface · 2025Article
- Article
- Neurotoxins Acting at Synaptic Sites: A Brief Review on Mechanisms and Clinical Applications.Toxins · 2022Review
- Botulinum toxin-A: A novel treatment for livedoid vasculopathy.JAAD case reports · 2022Article
- Review
- Update on Interventional Management of Neuropathic Pain: A Delphi Consensus of the Spanish Pain Society Neuropathic Pain Task Force.Medicina (Kaunas, Lithuania) · 2022Article
- Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients.American journal of ophthalmology case reports · 2020Article
- A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.Current pain and headache reports · 2020Review
- Botulinum toxin A treatment for post-herpetic neuralgia: A systematic review and meta-analysis.Experimental and therapeutic medicine · 2020Article
- Botulinum Neurotoxin for the Treatment of Neuropathic Pain.Frontiers in neurology · 2020Review
- Mechanisms of Botulinum Toxin Type A Action on Pain.Toxins · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis meta-analysis was performed to evaluate the efficacy and safety of botulinum toxin-A (BTX-A) for the treatment of neuralgia.
methodsWe searched PubMed, EMBASE, and Cochrane databases to identify randomized controlled trials (RCTs) comparing BTX-A treatment with saline for alleviating neuropathic pain. Primary outcome measures were pain scores up to 24 weeks after treatment. Secondary outcomes were hours of sleep, Short Form-36 (SF-36) life quality questionnaire, and adverse events. We used Review Manager 5.3 for the data analyses.
resultsTwelve RCTs were included (n=495). Pain scores in the BTX-A group were significantly lower compared to the saline group at 4 weeks (mean difference [MD] =-1.64, 95% CI [-3.21, -0.07],
conclusionBased on the current evidence, BTX-A may be an effective and safe option for the treatment of neuralgia. Due to the limited number of patients included in this meta-analysis, more trials are still needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.